|
|
|
09.01.26 - 07:00
|
Vår Energi ASA: Notice of extraordinary general meeting (Cision)
|
|
|
Sandnes, Norway, 9 January 2026: The board of directors of Vår Energi (OSE: VAR, the “Company”) hereby calls for an extraordinary general meeting (“EGM”) to be held on 30 January 2026 at 15:00 CET to approve a dividend for the fourth quarter of 2025, based on the Company's audited interim balance sheet and notes as per 30 September 2025.
Shareholders can participate in the EGM via webcast and also vote in advance or by proxy. The deadline for advance voting and proxy registration is 28 January 2026 at 15:00 CET. Only shareholders registered in Euronext VPS as of 23 January 2026 are entitled...
|
|
|
|
|
|
|
07.01.26 - 18:03
|
GENFIT Announces 2026 Financial Calendar (GlobeNewswire EN)
|
|
|
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026 - GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026....
|
|
|
|
|
06.01.26 - 18:15
|
GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N (GlobeNewswire EN)
|
|
|
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 6, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that G1090N – a small molecule and the Company's lead investigational drug candidate for Acute-On-Chronic Liver Failure (ACLF) – demonstrated a favorable Phase 1 safety profile, and a strong anti-inflammatory activity in ex-vivo studies....
|
|
|
|
|
06.01.26 - 07:03
|
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire EN)
|
|
|
January 6, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT....
|
|
|
|
|
|
|
|
|
|
|
22.12.25 - 15:01
|
Aker Solutions ASA: Reporting of transactions made by persons discharging managerial responsibilities (Cision)
|
|
|
December 22, 2025 – Aker Solutions ASA (“Aker Solutions”) has today allocated shares to primary insiders participating in the company's employee share purchase program for 2025.
Reference is made to the stock exchange release published earlier today, December 22, 2025, concerning the employee share purchase program and share allocation. For the December 2025 allocation, shares were sold at a price per share, excluding applicable discount, of NOK 30.1532 which equals the volume-weighted average share price of Aker Solutions on Euronext Oslo Børs from and including December 15, 2025, to and...
|
|
|
|
|
15.12.25 - 07:03
|
Proton Therapy New Standard of Care for Patients with Oropharyngeal Cancer (GlobeNewswire EN)
|
|
|
Louvain-La-Neuve, Belgium, December 15, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, is pleased to share today that, on December 11, The Lancet – one of the world's most renowned academic journals – published a landmark study that recommends proton therapy as a new standard of care for patients with oropharyngeal cancer. This study, led by MD Anderson Cancer Center, the world's leading hospital for cancer care, is the first-ever randomized controlled trial (RCT) to provide the highest level of evidence demonstrating the benefits of proton therapy over conventional radiotherapy for this indication....
|
|
|
12.12.25 - 19:54
|
Anabranch Capital Management, LP unterstützt die Wiederaufnahme der Notierung von SmartCraft ASA an der Nasdaq Stockholm (Business Wire)
|
|
|
STAMFORD, Conn.--(BUSINESS WIRE)--Es wird auf die Börsenmitteilung von SmartCraft ASA („SmartCraft” oder das „Unternehmen”) vom 1. Dezember 2025 bezüglich der geplanten Umnotierung von SmartCraft von der Euronext Oslo Børs an die Nasdaq Stockholm (die „Umnotierung”) und die Ankündigung einer grenzüberschreitenden Fusion zur Durchführung der Umnotierung verwiesen. Die von Anabranch Capital Management, LP („Anabranch“) verwalteten Fonds beabsichtigen, für den von den Vorständen von SmartCraft und seiner schwedischen hundertprozentigen Tochtergesellschaft SmartCraft Group AB (publ) beschlossenen Fusionsplan zu stimmen, um die Wiederaufnahme der Notierung auf der für Januar 2025 geplanten außerordentlichen Hauptversammlung der Gesellschaft (die „EGM“) zu erreichen. Anabranch beabsichtigt, mit allen Anabranch-Aktien, die zum Stichtag für die außerordentliche Hauptversammlung gehalten werden, für die durch den Fusionsplan bewirkte Wiederaufnahme der Börsennotierung zu stimmen. ...
|
|
|
12.12.25 - 16:30
|
Anabranch Capital Management, LP supports relisting of SmartCraft ASA to Nasdaq Stockholm (Business Wire)
|
|
|
STAMFORD, Conn.--(BUSINESS WIRE)--Reference is made to the stock exchange announcement by SmartCraft ASA ("SmartCraft" or the "Company") on 1 December 2025 regarding the contemplated relisting of SmartCraft from Euronext Oslo Børs to Nasdaq Stockholm (the "Relisting") and the announcement of a cross-border merger to effect the Relisting. Funds managed by Anabranch Capital Management, LP (“Anabranch”) intend to vote in favour of the merger plan resolved by the boards of SmartCraft and its Swedish wholly owned subsidiary, SmartCraft Group AB (publ), to effect the Relisting at the Company's extraordinary general meeting planned for January 2025 (the "EGM"). Anabranch intends to vote with all Anabranch shares held at the Record Date for the EGM in favour of the relisting effected by the merger plan. Funds managed by Anabranch currently hold approximately 15.9 million shares in SmartCraft.
Disclaimer: The views expressed are those of the authors and Anabranch Capit...
|
|
|
12.12.25 - 07:48
|
DOF Group ASA – Successful listing of bond issue (Cision)
|
|
|
DOF Group ASA (the "Company") is pleased to announce that it has successfully listed the bonds issued by the Company under the initial issue ("Initial Issue") of senior unsecured USD 150,000,000 bonds as part of the DOF Group ASA 8.125% senior unsecured USD 250,000,000 bonds 2025/2030 with ISIN NO NO0013647701, on Euronext Oslo Børs as of today.
The listing documents can be accessed here:
https://www.dof.com/documents/dof-group-asa-securities-note
https://www.dof.com/documents/dof-group-asa-registration-document
Contact information:
Eirik Vardøy, Investor Relations DOF Group...
|
|
|
11.12.25 - 07:03
|
China Gold Irradiation Introduces IBA′s sustainable X-ray irradiation technology to expand its production capacity (GlobeNewswire EN)
|
|
|
Louvain-la-Neuve, Belgium, December 11, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial advanced irradiation, announced today it has signed a contract with China Gold Irradiation (CGI), the largest high standard irradiation service company in China, to install a Rhodotron® in Jiaxing, Zhejiang Province, as a first step of the transition of China's irradiation processing industry to a new stage of high-quality development....
|
|
|
|